Astellas Submits New Drug Application for Zolbetuximab in Japan

Japanese pharmaceutical company Astellas Pharma has submitted a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare for zolbetuximab, an investigational Claudin 18.2-targeted monoclonal antibody being evaluated as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tu..